Ilić, Violeta (57189998261)Violeta (57189998261)IlićBogićević, Dragana (8279362500)Dragana (8279362500)BogićevićMiljković, Branislava (6602266729)Branislava (6602266729)MiljkovićJešić, Maja (24073164000)Maja (24073164000)JešićKovačević, Marijana (57190009373)Marijana (57190009373)KovačevićProstran, Milica (7004009031)Milica (7004009031)ProstranKovačević, Sandra Vezmar (57204567668)Sandra Vezmar (57204567668)Kovačević2025-07-022025-07-022016https://doi.org/10.1684/epd.2016.0821https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976427915&doi=10.1684%2fepd.2016.0821&partnerID=40&md5=544933cf5c447a0f10c428e468825933https://remedy.med.bg.ac.rs/handle/123456789/13457Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p<0.001) and free triiodothyronine (p<0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.ChildrenEpilepsyThyroid functionValproic acid